Pares stake in Inogent
Dai-ichi Karkaria announced that pursuant to the Call Option under the Joint Venture and Shareholders Agreement among GVK Biosciences (GVK Bio), Dai-Ichi Karkaria (the Company) and Inogent Laboratories (Inogent), dated 14 October 2005, GVK Bio has acquired balance 9,87,500 equity shares (6.12% of voting powers) of Inogent from the Company on 11 July 2014, at a consideration aggregating to Rs. 8.97 crore.Accordingly, the shareholding of the Company in Inogent after the acquisition will be NIL and the Agreement shall be treated as concluded.
Powered by Capital Market - Live News
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app